Step into Pharma’s Age of Uncertainty, where all is in flux. From the FDA’s shifting mood and the ripple effects of the IRA to commercial upheavals, dealmaking uncertainties and emerging R&D mechanisms, we’ve identified the pivotal forces that are redefining the pharma and biotech landscape out to 2028. Download Evaluate’s World Preview 2023: Pharma’s Age […]
Share:
Step into Pharma’s Age of Uncertainty, where all is in flux. From the FDA’s shifting mood and the ripple effects of the IRA to commercial upheavals, dealmaking uncertainties and emerging R&D mechanisms, we’ve identified the pivotal forces that are redefining the pharma and biotech landscape out to 2028.
Download Evaluate’s World Preview 2023: Pharma’s Age of Uncertainty report here.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
